As an increasing number of patients come forward with claims that their vision has been permanently impacted by weight loss jabs, eye experts have issued a vital statistical warni ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with type 2 ...

NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) officially describes vision loss caused by reduced blood flow to the optic nerve ...

A: An eye stroke is sudden vision loss caused by reduced blood flow to the optic nerve, and it usually leads to permanent blindness. A: Yes, but the study found Wegovy users have nearly five times ...

Please provide your email address to receive an email when new articles are posted on . The deep learning system demonstrated an AUC of 0.97, a sensitivity of 91.1%, a specificity of 93.4% and an ...

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a Maryland man who developed non-arteritic anterior ischemic optic neuropathy ...

Use of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) may be linked with an increased risk of the second most common form of optic neuropathy, a retrospective study suggested. Over a mean ...

Nonarteritic, anterior ischemic optic neuropathy is the most common form of ischemic optic neuropathy. 3,4 Typical presentation includes acute, unilateral, and painless loss of central and/or ...

A 65-year-old white woman presented with 9 months of intermittent “kaleidoscopic” visual disturbances and blurred vision upon ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay News — ...

People with type 2 diabetes starting semaglutide have more than a doubled risk for NAION versus those starting SGLT2is.

People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 ...